Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarcocimab tedromer - Kodiak Sciences

Next Previous
Drug Profile

Tarcocimab tedromer - Kodiak Sciences

Alternative Names: KSI-301

Latest Information Update: 25 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oligasis
  • Developer Kodiak Sciences
  • Class Antibodies; Biopolymers; Drug conjugates; Eye disorder therapies; Immunoconjugates
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 13 Nov 2025 Kodiak Sciences completes enrolment in the DAYBREAK trial for Wet age-related macular degeneration in USA and Puerto Rico (Intravitreous) (NCT06556368)
  • 13 Aug 2025 Efficacy data from a phase III DAYLIGHT trial in Wet age-related macular degeneration released by Kodiak Sciences
  • 10 Mar 2025 Kodiak Sciences completes enrollment in the phase III GLOW2 trial in Diabetic retinopathy in Puerto Rico and USA (Intravitreous) (NCT06270836)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top